Advancing powder compaction analysis with the new Gamlen D series
D-series analysers are supplied with new 'in-die' and 'out-of-die' compaction analysis software that generates tablet detachment and ejection data with full profiles.
Designed for advanced tableting research, Gamlen Tableting’s new flagship D series dynamic powder compaction analysers feature dwell time control from 90 milliseconds to 60 seconds. D-series analysers are supplied with new 'in-die' and 'out-of-die' compaction analysis software that generates tablet detachment and ejection data with full profiles including strain data, Heckel and Kawakita plots. An optional add-on, the Tablet Tensile Analyzer (TTA), automatically calculates tablet density and solid fraction, and tablet tensile fracture stress.
Michael Gamlen, Managing Director, commented: “The D-series will change the way scientists characterise materials. The key element of the D series is our unique dynamic compaction analysis software, which allows researchers to characterise the elasticity and plasticity of materials at each compaction event, as well as their lubricity and punch detachment behaviour. This is in addition to recording, in real-time, compaction and ejection profiles of an API, excipient, or drug formulation. Researchers will now be able to create a database of material-specific data to support a wide variety of investigations, such as screening for compatible excipients, and enabling accelerated formulation and process development and scale-up to manufacturing.”
Tablet tensile strength can be measured on a D-series instrument via an included high-sensitivity load cell, or alternatively by using the Gamlen Tablet Tensile Analyzer. The Gamlen Tablet Tensile Analyzer is a complementary stand-alone system which measures tablet fracture stress properties in addition to out-of-die weight and thickness of a tablet produced on a D-series instrument. The included TTA software package automatically captures all of these parameters and produces Compaction Triangle plots of compactibility, compressibility, and tabletability.
With a rapidly expanding product range, Gamlen Tableting has transformed the entire Gamlen product line to include the Gamlen M series, for small-scale manufacture of tablets under tightly controlled conditions, and the R series (formerly known as the GTP-1) to support fundamental tableting research and development in a university or company environment.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance